Zanubrutinib in Combination With Obinutuzumab (ZO) for Newly Diagnosed Follicular Lymphoma

This trial is testing a combination of two drugs — zanubrutinib (a targeted oral pill) and obinutuzumab (an infusion antibody) — in patients newly diagnosed with follicular lymphoma, a slow-growing type of non-Hodgkin lymphoma. The goal is to see if this chemotherapy-free combination can effectively control the disease. **You may be eligible if...** - You are 18 or older with newly diagnosed stage II-IV follicular lymphoma that requires treatment - Your performance status is acceptable (ECOG 0-2) - Your liver and kidney function are within acceptable limits - You have at least one measurable area of lymphoma on imaging **You may NOT be eligible if...** - Your lymphoma has transformed to a more aggressive type, involves the brain, or has been treated before - You have HIV or active hepatitis C - You have serious heart or bleeding problems, or required treatment with warfarin-type blood thinners - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.